Skip to content
Healthcare Industry News, Trends & Articles

News

Genomic Clinical Decision Support Market Size, Share, Trends, and Forecast, 2026-2036 | AI, EHR Integration, and Pharmacogenomics Drive 13.8% CAGR to USD 5.18 Billion by 2036

HNHealthcare News

Boost ROI through EHR-integrated pharmacogenomics, cloud delivery, AI-assisted curation and trial matching, targeting oncology and primary care opportunities.

Dublin, Nov. 16, 2026 (GLOBE NEWSWIRE) -- "Genomic Clinical Decision Support Market Size, Share, and Trends - Forecast to 2036" has been added to ResearchAndMarkets.com's offering.

Global Genomic Clinical Decision Support Market to Reach USD 5.18 Billion by 2036

The global genomic clinical decision support market was valued at USD 1.24 billion in 2025 and is estimated to reach USD 1.42 billion in 2026. The market is projected to grow to USD 5.18 billion by 2036, registering a CAGR of 13.8% during the forecast period 2026-2036.

The report examines genomic clinical decision support software, knowledge bases and content, and associated services across oncology, pharmacogenomics, rare and inherited diseases, hereditary cancer and cardiovascular risk, reproductive and prenatal health, and other clinical applications. It also assesses EHR integration, clinical guidelines, regulation, reimbursement, business models, competition, and emerging growth opportunities. Genomic testing revenue, secondary analysis, data storage, imaging AI, general clinical decision support without genomic content, and consumer genetic reports are excluded.

Market Drivers and Growth Opportunities

Oncology remains a major driver of market growth as comprehensive genomic profiling, liquid biopsy, molecular residual disease testing, and biomarker-driven therapies become increasingly important in cancer care. The expanding number of targeted therapies, immunotherapies, clinical guidelines, and biomarker-led trials is increasing demand for platforms that support therapy selection, interpretation, and clinical trial matching.

Pharmacogenomics represents another significant growth opportunity. Health systems implementing preemptive testing require clinical decision support that stores genomic results and delivers relevant drug-gene alerts within prescribing workflows. The NHS PROGRESS pharmacogenomics trial, operating across 20 general practices in England, found that 93% of participants had a clinically relevant variant in at least one of the four genes studied. Approximately 80% of the guidance presented was followed, while 35% of participants had a prescription changed.

EHR genomic modules and HL7 FHIR Genomics standards are supporting structured data exchange, automated alerts, and population-level patient identification. AI and large language models may further accelerate literature review, evidence extraction, clinical summarization, curation, and trial matching. In January 2026, the U.S. Food and Drug Administration issued revised CDS software guidance clarifying which clinician-facing functions may be exempt from device requirements under the 21st Century Cures Act.

Market adoption continues to face reimbursement limitations, alert fatigue, interoperability gaps, inconsistent variant classifications, and the cost of expert knowledge curation. Many genomic results are still delivered as PDFs rather than discrete data, restricting automation and integration. Vendors must demonstrate improvements in safety, clinical outcomes, efficiency, and workflow performance to support investment by health systems.

Segment Analysis

  • Component: Software is expected to hold the largest market share in 2026, supported by adoption among laboratories, cancer centers, and health systems. Services are projected to record the highest CAGR due to demand for EHR and laboratory integration, implementation support, expert interpretation, content curation, and workflow optimization.
  • Application: Oncology is expected to lead the market in 2026 because of high profiling volumes and growing use of biomarker-linked therapies. Pharmacogenomics is forecast to expand at the highest CAGR as preemptive testing and prescribing-system integration gain momentum.
  • Integration type: Standalone solutions, including web-based tools and laboratory portals, are expected to account for the largest share in 2026. EHR-integrated solutions are anticipated to grow fastest as health systems prioritize guidance within existing clinical and prescribing workflows.
  • Deployment mode: Cloud-based deployment is expected to lead and grow faster than on-premise deployment, reflecting continuous content updates, expanding cloud-hosted EHR adoption, and lower implementation costs for smaller healthcare organizations.
  • End user: Hospitals & health systems are projected to retain the largest share in 2026. Ambulatory & primary care practices are expected to achieve the highest CAGR as pharmacogenomics and hereditary risk assessment expand beyond specialist settings.

Regional Market Outlook

North America is expected to remain the largest genomic clinical decision support market in 2026, supported by substantial oncology testing volumes, advanced EHR adoption, academic pharmacogenomic programs, and the presence of major technology and testing companies.

Europe holds a significant share, benefiting from the NHS Genomic Medicine Service, the NHS PROGRESS trial, national pharmacogenetic guidelines in the Netherlands, and established industry participants. Regulatory requirements under the EU IVDR and MDR remain important considerations for software providing diagnostic or therapeutic information.

Asia-Pacific is projected to register the highest CAGR through 2036. Growth is being supported by expanding oncology genomic testing in China, Japan, South Korea, and Australia, national cancer genomic medicine coverage in Japan, population genomics initiatives in Singapore, broader EHR adoption, and increased interest in pharmacogenomics. Gulf genome projects in Saudi Arabia, the UAE, and Qatar are supporting demand in the Middle East & Africa, while oncology genomic testing in Brazil and Mexico is contributing to Latin American growth.

Competitive Landscape

The market is moderately fragmented, with EHR vendors, interpretation software providers, testing companies, and genomic content specialists competing across applications and regions. Key competitive factors include curated knowledge depth, content currency, EHR and laboratory integration, clinical trial matching, regulatory compliance, usability, and evidence of clinical utility.

Leading companies are embedding genomic results into EHR workflows, expanding knowledge bases, applying AI to interpretation and curation, and combining testing, decision support, and data services. Companies profiled include Epic Systems Corporation, Oracle Corporation through Oracle Health, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Illumina, Inc., Tempus AI, Inc., SOPHiA GENETICS SA, and Velsera, Inc.

Strategic Value of the Report

  • Provides global market size estimates and forecasts through 2036.
  • Evaluates oncology profiling, pharmacogenomic prescribing, and EHR genomic module adoption.
  • Assesses reimbursement, interoperability, alert fatigue, regulation, and knowledge maintenance challenges.
  • Identifies high-growth opportunities by component, application, integration type, deployment mode, end user, and geography.
  • Tracks preemptive pharmacogenomics, AI-assisted curation, clinical trial matching, and HL7 FHIR Genomics integration.
  • Benchmarks leading EHR vendors, software providers, testing companies, and content specialists.
  • Supports product development, partnership, investment, market entry, and commercialization strategies.

Key Topics Covered:

1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders

2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Industry Experts
2.2.2.2. Country-/Region-Level Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach
2.3.2. Top-Down Approach
2.3.3. Forecast Methodology
2.4. Data Triangulation
2.5. Assumptions

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Growth of Comprehensive Genomic Profiling in Oncology
4.2.1.2. Expansion of Pharmacogenomic Testing and Prescribing Integration
4.2.1.3. Increasing Complexity of Genomic Results
4.2.1.4. Integration of Genomic Data into Electronic Health Records
4.2.2. Restraints
4.2.2.1. Limited Reimbursement for Pharmacogenomic Testing and Decision Support
4.2.2.2. Alert Fatigue and Workflow Disruption
4.2.3. Opportunities
4.2.3.1. Preemptive Pharmacogenomics at Population Scale
4.2.3.2. AI and Large Language Models for Evidence Curation and Interpretation
4.2.3.3. Clinical Trial Matching and Real-World Evidence
4.2.3.4. Genomic Decision Support in Primary Care, Cardiology, and Rare Diseases
4.2.4. Challenges
4.2.4.1. Maintaining Current and Consistent Knowledge Bases
4.2.4.2. Structured Genomic Data Exchange and Interoperability
4.2.5. Trends
4.2.5.1. Shift from Report-Based to EHR-Embedded Decision Support
4.2.5.2. Convergence of Genomic Testing, Data, and Decision Support
4.2.5.3. Preemptive and Lifetime Use of Genomic Results
4.3. Technology Landscape
4.3.1. Curated Genomic Knowledge Bases
4.3.2. Oncology Therapy and Clinical Trial Matching Engines
4.3.3. Pharmacogenomic Alerting and Dosing Engines
4.3.4. EHR Genomic Modules and HL7 FHIR Genomics
4.3.5. AI and Large Language Models in Genomic Interpretation
4.4. Evidence and Guideline Landscape
4.4.1. Oncology Guidelines and Biomarker-Drug Associations
4.4.2. CPIC and DPWG Pharmacogenomic Guidelines
4.4.3. Variant Classification Standards
4.5. Case Studies: Health System and National Program Implementations
4.6. Value Chain Analysis
4.6.1. Genomic Testing and Result Generation
4.6.2. Knowledge Curation
4.6.3. Decision Support Software
4.6.4. EHR and Workflow Integration
4.6.5. Clinical Action and Outcomes
4.7. Regulatory Landscape
4.7.1. FDA Clinical Decision Support Software Guidance (2026)
4.7.2. EU IVDR and MDR for Software
4.7.3. Data Privacy and Interoperability Rules
4.7.4. Reimbursement Landscape
4.8. Porter's Five Forces Analysis
4.9. Pricing and Business Model Analysis

5. Genomic Clinical Decision Support Market, by Component
5.1. Introduction
5.2. Software
5.2.1. Standalone CDS Platforms
5.2.2. EHR-Embedded Genomic Modules
5.3. Knowledge Bases & Content
5.4. Services
5.4.1. Implementation & Integration Services
5.4.2. Curation & Interpretation Services

6. Genomic Clinical Decision Support Market, by Application
6.1. Introduction
6.2. Oncology
6.2.1. Therapy Selection
6.2.2. Clinical Trial Matching
6.2.3. Disease Monitoring
6.3. Pharmacogenomics
6.4. Rare & Inherited Diseases
6.5. Hereditary Cancer & Cardiovascular Risk
6.6. Reproductive & Prenatal Health
6.7. Other Applications

7. Genomic Clinical Decision Support Market, by Integration Type
7.1. Introduction
7.2. EHR-Integrated
7.3. Standalone

8. Genomic Clinical Decision Support Market, by Deployment Mode
8.1. Introduction
8.2. Cloud-Based
8.3. On-Premise

9. Genomic Clinical Decision Support Market, by End User
9.1. Introduction
9.2. Hospitals & Health Systems
9.3. Clinical & Reference Laboratories
9.4. Ambulatory & Primary Care Practices
9.5. Specialty Clinics & Cancer Centers
9.6. Other End Users

10. Genomic Clinical Decision Support Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. U.K.
10.3.2. Germany
10.3.3. France
10.3.4. Netherlands
10.3.5. Italy
10.3.6. Spain
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. Australia
10.4.5. Singapore
10.4.6. India
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
10.6.1. Saudi Arabia
10.6.2. UAE
10.6.3. Qatar
10.6.4. Rest of Middle East & Africa

11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Market Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Players
11.5. Market Share/Rank Analysis, by Key Player, 2025

12. Company Profiles
12.1. Epic Systems Corporation
12.2. Oracle Corporation (Oracle Health)
12.3. F. Hoffmann-La Roche Ltd
12.4. QIAGEN N.V.
12.5. Illumina, Inc.
12.6. Tempus AI, Inc.
12.7. SOPHiA GENETICS SA
12.8. Velsera, Inc.

13. Appendix
13.1. Related Reports
13.2. Customization Options

List of Tables [298]
List of Figures [41]

For more information about this report visit https://www.researchandmarkets.com/r/jfor53

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900